Psagot Investment House
VC Fund
Tel Aviv, Israel
Psagot Investment House is a VC fund in Tel Aviv focused on Biotechnology and Railroad. The Psagot Investment House is an Israeli investment firm and the country's largest pension fund manager.
- Total investments:
- 6
- Last investment:
- Lead investor:
- 17%
Last updated:
For AI agents: llms.txt
Industries Psagot Investment House invests in
BiotechnologyRailroadSoftwareWirelessSmart Home
Stages Psagot Investment House invests in
Post-IPO EquityFunding RoundSeries C
Countries Psagot Investment House invests in
IsraelUnited States
Investment Focus
Industry
- Biotechnology 2 (33%)
- Railroad 1 (17%)
- Software 1 (17%)
- Wireless 1 (17%)
- Smart Home 1 (17%)
Stage
- Post-IPO Equity 3 (50%)
- Funding Round 2 (33%)
- Series C 1 (17%)
Country
- Israel 3 (50%)
- United States 2 (33%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Veev
|
Veev is a building technology company that reinvents the way homes are built and experienced. Veev's home operating system creates room-specific lighting, shade, and climate control and also offers protection against intrusion and cybercrime, thereby providing clients a one-stop solution to all their smart housing requirements.Key componentsof the Veev panelized building system include the use of light gauge steel (LGS) for framing, high-performance acrylic (HPA) for surfaces and millwork, radiant climate control systems, and a digital home ecosystem. The company is currently focused on high-performance multifamily and accessory dwelling unit (ADU) products. The current development pipeline totals more than 230 units and 620,000 gross building square feet. | $100M / Mar 23, 2021 | |
|
Veev
|
Veev is a building technology company that reinvents the way homes are built and experienced. Veev's home operating system creates room-specific lighting, shade, and climate control and also offers protection against intrusion and cybercrime, thereby providing clients a one-stop solution to all their smart housing requirements.Key componentsof the Veev panelized building system include the use of light gauge steel (LGS) for framing, high-performance acrylic (HPA) for surfaces and millwork, radiant climate control systems, and a digital home ecosystem. The company is currently focused on high-performance multifamily and accessory dwelling unit (ADU) products. The current development pipeline totals more than 230 units and 620,000 gross building square feet. | $100M / Series C / Mar 23, 2021 | |
Steakholder Foods
|
Steakholder ($STKH) is a publicly traded company on Nasdaq, 3D printing a new frontier in protein manufacturing. Our mission is to provide manufacturing solutions that craft sustainable, delicious alternative meat and fish, reducing environmental impact and promoting health. We aim to revolutionize food production, providing industry-standardmachinery and premix blends for plant-based food. Steakholder’s innovative techniques mimic the taste and texture of traditional foods. We are pioneers in the plant-based and cultivated meat industry, leveraging cutting-edge 3D printing technology to create sustainable, high-quality food solutions that go beyond simple imitation, aiming to capture the essence and nutritional benefits of traditional beef, poultry, and seafood. We are committed to supporting our partners in achieving their goals by providing them with the tools and expertise needed to succeed in a rapidly growing market. Whether you are looking to develop new plant-based products or enhance your existing offerings, Steakholder has the solutions to help you lead in the industry. | $7M / Nov 02, 2020 | |
DarioHealth
|
DarioHealth Corp is a digital health company. It is engaged in the development and commercialization of patented and proprietary technology that provides consumers with laboratory-testing capabilities using smartphones and other mobile devices. The company's product, Dario Blood sugar monitor is a mobile, real-time, cloud-based, diabetesmanagement solution based on a multi-featured software application combined with a blood glucose monitoring device. The group operates internationally and derives revenues from the sale of its Dario smart meter and related device-specific disposables test strip cartridges and lancets. The company generates the majority of the revenue. | $28.6M / Post-IPO Equity / Jul 21, 2020 | |
ElectReon
|
ElectReon revolutionizes E- mobility with the ultimate goal of eliminating the dependency on oil. It is paving the way for future green e-mobility solutions with a unique “Smart road technology”, by developing a Dynamic Wireless Electrification System for electric transportation.Its technology reduces the need for a large battery in the vehicleand powers it wirelessly via minimal infrastructure located under the driving lane. Eliminating the need to stop for recharging or refueling the vehicle during the day.Once the system has been deployed in the main roads for public transportation then it can serve as a platform for all kind of vehicles eliminating the initial costs. In addition, ElectReon can harvest energy due to vehicle braking and transfer it back to the electricity grid, it reduces the total amount of energy consumed by the transportation sector. | $50M / Post-IPO Equity / Jul 02, 2020 | |
Protalix BioTherapeutics
|
Protalix is a biopharmaceutical company that is revolutionizing the development and manufacturing of recombinant therapeutic proteins through its ProCellEx® plant cell-based protein expression system. Using ProCellEx, Protalix is focused on the development and commercialization of a proprietary pipeline of novel and biosimilar proteins that targetlarge, established pharmaceutical markets and that rely upon known biological mechanisms of action. Protalix’s initial commercial focus is on complex therapeutic proteins for the treatment of genetic disorders, such as Gaucher disease and Fabry disease. Protalix is also advancing additional recombinant biopharmaceutical drug development programs, including a TNF inhibitor for inflammatory diseases.Protalix’s pipeline is led by ELELYSO™(taliglucerase alfa for injection), which received approval from the U.S. Food and Drug Administration on May 1, 2012. ELELYSO is the first FDA-approved plant cell-based recombinant therapeutic protein. Protalix has partnered with Pfizer for worldwide development and commercialization of ELELYSO, excluding Israel, where Protalix has retained full rights. Marketing applications for taliglucerase alfa have been submitted for Europe, Israel, Brazil and Australia, with additional regulatory submissions in progress. | $43.7M / Post-IPO Equity / Mar 12, 2020 |
Co-Investors
Migdal Insurance and Financial Holdings
3 deals together
More Investment House
3 deals together
Shavit Capital
2 deals together
AFCON Software
1 deal together
Alrov Group
1 deal together
Excellence Nessuah Investment House
1 deal together
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
SaaS Investors
99,274 investors
Software Investors
50,021 investors
Hardware Investors
40,144 investors
Consumer Investors
32,380 investors
Transportation Investors
27,893 investors
Biotech Investors
21,775 investors
Proptech Investors
20,668 investors
Biotechnology Investors
19,370 investors
SaaS VC Funds
61,208 investors
FAQ
What does Psagot Investment House invest in?
Psagot Investment House invests primarily in Biotechnology, Railroad and Software startups, most often at Post-IPO Equity and Funding Round stage. Most of the 6 investments tracked by Shizune back companies in Israel. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did Psagot Investment House last invest?
The most recent investment recorded for Psagot Investment House closed in Mar 2021. Shizune tracks 6 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
